Activities

- Introduction to Dyslipidemia Burden & Gaps
- LDL-C Reduction Guidelines and Targets
- Use of PCSK9i in Very High Risk Patients with Diabetes

• Understand the underlying causes of gastrointestinal disturbances in infants....

HR+ HER2- Breast cancer treatment landscape, MonarchE update and patient profile

Obesity is increasingly recognized as a key comorbidity in psoriatic disease, with important implications for both psoriasis (PsO) and psoriatic arthritis (PsA). Evidence shows that excess weight not only contributes to systemic inflammation but also worsens disease activity, reduces treatment response, and increases the risk of associated comorbidities such as cardiovascular disease and diabetes. Despite these links, obesity remains underrecognized and undertreated in patients with psoriatic disease.
This educational activity will explore the complex relationship between obesity, PsO, and PsA.

From Clinical Trials to RWE in PsO & AA

From Clinical Trials to RWE in PsA & PsO

The activity will focus on the earliest guidelines for proper use of biomarkers for AD in primary and secondary care

The activity will focus on the earliest guidelines for proper use of biomarkers for AD in primary and secondary care

•Highlights the ADA/EASD 2022 update which emphasizes the importance of managing glycemia, weight, cardiovascular risk factors in Type 2 Diabetes.

The SpA Forum aims to provide healthcare professionals with scientific data on the pathophysiology, clinical management, and treatment optimization of PsA and AxSpa with expert led discussions highlighting the evidence of IL-17i effect on pain and inflammation mechanisms, disease progression from psoriasis to psoriatic arthritis, and clinical case scenarios to bridge theory with practical management.
The forum will foster regional experts to address unmet needs in multidisciplinary management, and patient-centered care, supporting best clinical practice and improved patient outcomes in PsA and AxSpa.

Clinical Documentation Improvement is at the heart of modern healthcare transformation.
Accurate and complete documentation not only ensures patient safety but also drives fair reimbursement, supports quality metrics, and strengthens clinical research.
In an era of digital health and data-driven decision-making, CDI empowers clinicians and healthcare teams to translate patient care into clear, reliable, and actionable records.
This project introduces learners to the foundations, best practices, and evolving role of CDI, highlighting its critical impact on quality of care and the future of healthcare systems.

Event on Atopic dermatitis down / Keep it down and
Transition from Clinical Trials to RWE in Alopecia Areata (AA) & to be presented by Dr. Sultan Aqueel whole session will be Chaired by Dr. MOHAMED Al Shahrani

KSA webinar on Atopic dermatitis down / Keep it down to be presented by Dr Awadh Al Amri and Co speaker Dr. Aymen Alharbi on Clinical cases to RWE in Plaque Psoriasis (PsO) & whole session will be Chaired by Dr FAWAZ HAMDI ALJEHANI

From Clinical Trials to RWE in PsO, PsA and RA

What are real-world data adding to our understanding of patient populations under-represented in RCTs? (PSOHO 24 Month)
How are real-world evidence and experiences shaping clinical practice? (Patient Cases)

Obesity as a chronic disease: bridging pathophysiology and epidemiology, discussing full spectrum of obesity related complications and current obesity management practices, as well as what we can do to help people living with obesity

Mentioned in the attachment

This event will feature leading experts sharing evidence-based strategies and innovative approaches to simplify diabetes management care.
BREAKING THROUGH THE COMPLEXITY OF LIVING WITH TYPE 2 DIABETES.

From Clinical Trials to RWE in PsO, PsA and RA